See Full Document Text
GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS
RAJYA SABHA
UNSTARRED QUESTION NO. 1949
TO BE ANSWERED ON THE 10th MARCH, 2026
Bio pharma SHAKTI scheme
1949 Shri Neeraj Shekhar:
Will the Minister of Chemicals and Fertilizers be pleased to state:
(a) whether Government has announced the Biopharma SHAKTI scheme and has allocated
₹10,000 crore over five years to establish India as a global hub for biologics and biosimilars;
(b) if so, the details thereof; and
(c) the manner in which it would benefit the Indian pharma industry?
ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND
FERTILIZERS
(SMT. ANUPRIYA PATEL)
(a) & (b): With a view to strengthening the domestic biopharmaceutical sector and enhancing
global competitiveness in biologics and biosimilars, the Government has announced the
Biopharma SHAKTI scheme with an outlay of ₹10,000 crore over five years with an objective
to build a globally competitive domestic ecosystem for biologics and biosimilars to support
affordable healthcare in India and enable India to emerge as a global biopharma manufacturing
and innovation hub.
(c): India’s disease burden is observed to be shifting towards non-communicable diseases, like
diabetes, cancer and autoimmune disorders. Biologic medicines are key to longevity and
quality of life at affordable costs. To develop India as a global Biopharma manufacturing hub,
an initiative like Biopharma SHAKTI for the biopharma sector is generally intended to benefit
the Indian pharma industry in following manner:
i. The initiative aims to support domestic development and manufacturing of
high-value biopharmaceutical products and medicines, reduce import dependence, and
enhance India’s competitiveness in global biologics supply chain.
ii. Expansion and strengthening of Biopharma-focused network through
establishment of three new National Institutes of Pharmaceutical Education & Research
(NIPERs) and upgradation of seven existing NIPERs will address growing requirement
of specialised human resource in biopharma research , development, manufacturing and
regulation.
iii. Creation of large-scale clinical research ecosystem with focus on improving
India’s capacity to conduct advanced clinical trials.
iv. The Central Drugs Standard Control Organisation (CDSCO) will be reinforced
to strengthen regulatory framework which will enable faster, globally credible
approvals by strengthening the CDSCO by creating a dedicated Scientific Review
Cadre. It will reduce no. of days currently being taken for regulatory approvals.v. The initiative focuses on early-stage innovation funding and structured equity
support to help startups and industry take promising candidates from concept through
key development milestones.
*****